Want to see SE:QLINEA full AI Analyst Report?
QLINEA Stock Chart & Stats
kr29.00
>-kr0.01(-3.85%)
At close: 4:00 PM EST
kr29.00
>-kr0.01(-3.85%)
Day’s Range― - ―
52-Week Rangekr14.55 - kr59.76
Previous CloseN/A
Volume6.05M
Average Volume (3M)13.43K
Market Cap
kr323.08M
Enterprise Value-kr97.88M
Total Cash (Recent Filing)kr186.77M
Total Debt (Recent Filing)kr11.68M
Price to Earnings (P/E)―
Beta2.70
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.20
Shares Outstanding18,949,081
10 Day Avg. Volume10,725
30 Day Avg. Volume13,430
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr76.80M
Bulls Say, Bears Say
Bulls Say
Recurring 'razor-and-blades' ModelA platform-plus-consumables model creates durable recurring revenue as installed instruments drive ongoing test cartridge and reagent sales. Over months this supports revenue visibility, unit economics leverage as installed base grows, and potential high margin conversion once scale is reached.
Automated Diagnostics PlatformOwning an automated platform for rapid pathogen ID and antimicrobial susceptibility addresses structural hospital and lab demand for faster sepsis diagnostics. This product-market fit supports long-term adoption, differentiation versus manual workflows, and recurring consumable pull-through.
Low Financial LeverageVery low debt reduces near-term solvency risk and interest burdens, preserving flexibility to fund R&D, commercial expansion, or absorb working-capital shocks. For a cash-burning medtech, light leverage makes capital raises less constrained by debt covenants and reduces refinancing risk.
Bears Say
High Cash BurnMaterial negative operating and free cash flow indicate the company is consuming cash rapidly to fund operations. Sustained burn pressures runway, creates dependency on external financing, risks dilution or constrained investment in commercialization, and limits ability to sustain losses long-term.
Persistent Unprofitable MarginsDeeply negative gross profit and large operating losses show the business has not achieved viable unit economics. Without margin improvement or scale-driven cost reductions, the model cannot convert recurring revenue into sustainable profitability, threatening long-term viability.
Modest, Volatile RevenueLow and uneven revenue (~9.9M TTM) limits scale benefits for consumables and prevents absorption of fixed R&D and commercial costs. Modest growth slows installed-base expansion, restricting recurring revenue ramp and making it harder to achieve the scale needed for margin recovery.
Q-linea AB News
QLINEA FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was kr14.55 and its highest was kr59.76 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is kr323.08M.
When is Q-linea AB’s upcoming earnings report date?
Q-linea AB’s upcoming earnings report date is Oct 30, 2026 which is in 102 days.
How were Q-linea AB’s earnings last quarter?
Q-linea AB released its earnings results on Jul 10, 2026. The company reported -kr1.58 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 18,949,081 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Q-linea AB reported an EPS of -kr1.58 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.453%.
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in SE:QLINEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q-linea AB
Q-linea AB (publ), founded in 2008 and based in Uppsala, Sweden, specializes in developing diagnostic instruments and associated consumables for infection detection. The company crafts advanced in vitro diagnostic platforms, specifically engineered to identify infectious diseases. A key product is ASTar, an innovative system designed to rapidly assess antibiotic susceptibility in positive blood cultures. Q-linea's overarching mission is to deliver cutting-edge solutions to healthcare professionals.
Technical Analysis
Vicore Pharma Holding AB
―
Isofol Medical AB
―
Biovica International AB Class B
―
Doxa AB
―
Guard Therapeutics International AB
―